Advanced Oncotherapy plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVO.L research report →
Companywww.avoplc.com
Advanced Oncotherapy plc, together with its subsidiaries, engages in the designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties.
- CEO
- Nicolas Serandour
- IPO
- 2006
- Employees
- 174
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $9.50M
- P/E
- -0.19
- P/S
- 0.00
- P/B
- 0.11
- EV/EBITDA
- -2.74
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -66.81%
- ROIC
- -17.46%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-35,248,716 · -16.21%
- EPS
- $-0.09 · 7.80%
- Op Income
- $-23,736,754
- FCF YoY
- -40.40%
Performance & Tape
- 52W High
- $25.75
- 52W Low
- $1.75
- 50D MA
- $0.61
- 200D MA
- $6.42
- Beta
- 0.06
- Avg Volume
- 543.97K
Get TickerSpark's AI analysis on AVO.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AVO.L Coverage
We haven't published any research on AVO.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AVO.L Report →